|
KMID : 1170320130190010023
|
|
Korean Journal of Health Economics and Policy
2013 Volume.19 No. 1 p.23 ~ p.39
|
|
|
Reimbursement Status and Challenges with Personalized Medicine
|
|
Moon You-Jung
Yu Su-Yeon
Kwon Jun-Seong
Yang Bong-Min
|
|
|
Abstract
|
|
|
|
Customized medical therapy, Personalized Medicine (PM) which selects the patients based on genetic variation is now spotlighted. If the type of PM is divided by the usage, its usage can be divided into increasing its therapeutic effects and reducing the side effects. Type of PM can also be divided into treatment groups such as anticancer drug, cardiovascular agents, and AIDS antiretroviral drugs. The strengths of PM are increasing therapeutic effects and reducing side effects. These advantages of PM provide sufficient incentives for pharmaceutical companies to develop more PM. However, there are both opportunities and challenges for healthcare reimbursement policy and emerging market. Even with the recognition of certain clinical advantages of PM, payers may be reluctant to invest in PM because of embedded uncertainty on resource savings. It will therefore be necessary to develop reimbursement schemes which reflect the characteristics of PM at the system level. This review is a first step, hopefully, toward such a development.
|
|
|
KEYWORD
|
|
|
Personalized Medicines, Targeted Therapies, Reimbursement
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|